Developing a Kinder & Gentler More Efficacious CEACAM5 ADC

• Contextualising lessons learned from the current ADC clinical development landscape and advocating for an enhanced focus on addressing tolerability to improve ADC performance and success for patients
• Pursuing less toxic ADC development to evolve dosing to be equivalent to naked antibody therapies and expand therapeutic index
• Highlighting differentiation strategy for kinder and gentler ADC development, headlined with preclinical profile of KIVU-305 against solid tumours

Speakers:

Ann MacLaren

Executive Vice President & Head, Translational Medicine

Kivu BioScience, Inc.